ES2675375T3 - Anticuerpos monoclonales contra claudina 18 para el tratamiento del cáncer - Google Patents

Anticuerpos monoclonales contra claudina 18 para el tratamiento del cáncer Download PDF

Info

Publication number
ES2675375T3
ES2675375T3 ES08758782T ES08758782T ES2675375T3 ES 2675375 T3 ES2675375 T3 ES 2675375T3 ES 08758782 T ES08758782 T ES 08758782T ES 08758782 T ES08758782 T ES 08758782T ES 2675375 T3 ES2675375 T3 ES 2675375T3
Authority
ES
Spain
Prior art keywords
monoclonal antibodies
antibodies against
cancer treatment
against claudin
cld18a2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08758782T
Other languages
English (en)
Inventor
Ugur Sahin
Özlem TÜRECI
Gunda Brandenburg
Dirk Usener
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH
Astellas Pharma Inc
Original Assignee
TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH, Astellas Pharma Inc filed Critical TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH
Application granted granted Critical
Publication of ES2675375T3 publication Critical patent/ES2675375T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un anticuerpo que tiene la capacidad de unirse a CLD18A2 y de mediar en la muerte y/o inhibición de la proliferación de células que expresan CLD18A2, en donde dicho anticuerpo es para usar en un método para prevenir o tratar un tumor de Krukenberg, en donde dicha CLD18A2 es un polipéptido que tiene la secuencia de aminoácidos según la SEQ ID NO: 2.
ES08758782T 2007-05-29 2008-05-27 Anticuerpos monoclonales contra claudina 18 para el tratamiento del cáncer Active ES2675375T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93209907P 2007-05-29 2007-05-29
EP07010622A EP1997832A1 (en) 2007-05-29 2007-05-29 Monoclonal antibodies against Claudin-18 for treatment of cancer
PCT/EP2008/004197 WO2008145338A2 (en) 2007-05-29 2008-05-27 Monoclonal antibodies against claudin-18 for treatment of cancer

Publications (1)

Publication Number Publication Date
ES2675375T3 true ES2675375T3 (es) 2018-07-10

Family

ID=38650052

Family Applications (2)

Application Number Title Priority Date Filing Date
ES18168460T Active ES2940775T3 (es) 2007-05-29 2008-05-27 Anticuerpos monoclonales contra claudina 18 para el tratamiento del cáncer
ES08758782T Active ES2675375T3 (es) 2007-05-29 2008-05-27 Anticuerpos monoclonales contra claudina 18 para el tratamiento del cáncer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES18168460T Active ES2940775T3 (es) 2007-05-29 2008-05-27 Anticuerpos monoclonales contra claudina 18 para el tratamiento del cáncer

Country Status (24)

Country Link
US (1) US8425902B2 (es)
EP (4) EP1997832A1 (es)
JP (3) JP5816431B2 (es)
KR (3) KR101693365B1 (es)
CN (2) CN101687929B (es)
BR (1) BRPI0811907A2 (es)
CA (1) CA2687206C (es)
DK (1) DK3401334T5 (es)
ES (2) ES2940775T3 (es)
FI (1) FI3401334T3 (es)
HR (1) HRP20230282T3 (es)
HU (1) HUE061795T2 (es)
IL (3) IL201666A (es)
LT (1) LT3401334T (es)
MX (1) MX2009012906A (es)
NZ (1) NZ581365A (es)
PL (1) PL3401334T3 (es)
PT (1) PT3401334T (es)
RS (1) RS64065B1 (es)
RU (2) RU2682285C2 (es)
SG (1) SG183773A1 (es)
SI (1) SI3401334T1 (es)
WO (1) WO2008145338A2 (es)
ZA (1) ZA200907675B (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6358588A (ja) * 1986-08-29 1988-03-14 Toshiba Corp バ−コ−ド読取装置
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) * 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
CA2711843C (en) 2007-12-20 2018-11-13 Laboratory Corporation Of America Holdings Her-2 diagnostic methods
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
JP2011523853A (ja) 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
AR072000A1 (es) 2008-06-03 2010-07-28 Abbott Lab Proteinas de union multivalentes con capacidad de unir dos o mas antigenos y usos de la misma
BRPI0915448A2 (pt) 2008-07-08 2015-11-10 Abbott Lab imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas
US8470542B2 (en) 2008-12-01 2013-06-25 Laboratory Corporation Of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
WO2010094499A1 (en) 2009-02-20 2010-08-26 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
AU2010242840B2 (en) * 2009-05-01 2014-04-17 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
KR20120060877A (ko) 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
TW201119676A (en) 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP3305813B1 (en) 2009-11-11 2020-01-15 Ganymed Pharmaceuticals GmbH Antibodies specific for claudin 6 (cldn6)
AU2011229518B2 (en) 2010-03-16 2015-09-24 Biontech Protein Therapeutics Gmbh Tumor vaccination involving a humoral immune response against self-proteins
EP2366709A1 (en) * 2010-03-16 2011-09-21 BioNTech AG Tumor vaccination involving a humoral immune response against self-proteins
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
SG187938A1 (en) 2010-08-26 2013-04-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
JP6169495B2 (ja) * 2011-02-07 2017-07-26 アガミン・エルエルシー 妊娠関連高血圧性障害を治療または予防するための方法およびシステム
WO2012149356A2 (en) * 2011-04-29 2012-11-01 Apexigen, Inc. Anti-cd40 antibodies and methods of use
HUE028603T2 (en) 2011-05-13 2016-12-28 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
CN104159920A (zh) 2011-12-30 2014-11-19 艾伯维公司 针对il-13和/或il-17的双重可变结构域免疫球蛋白
WO2013167153A1 (en) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
EP3725810B1 (en) 2012-05-23 2022-07-06 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP4556071A3 (en) * 2012-05-23 2025-08-27 Astellas Pharma, Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174403A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
MY171664A (en) 2012-11-01 2019-10-22 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof
NZ746691A (en) 2012-11-13 2020-08-28 Astellas Pharma Inc Agents for treatment of claudin expressing cancer diseases
WO2014127785A1 (en) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
HRP20221319T1 (hr) * 2013-02-20 2022-12-23 Astellas Pharma Inc. Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
CN120137056A (zh) * 2014-07-17 2025-06-13 恺兴生命科技(上海)有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
CN118165113B (zh) * 2016-04-26 2025-10-28 恺兴生命科技(上海)有限公司 一种改善免疫应答细胞功能的方法
EP3538141A4 (en) 2016-11-10 2020-07-15 Merck Sharp & Dohme Corp. LIGAND ILT3
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
WO2018148595A1 (en) * 2017-02-10 2018-08-16 Washington University Antibodies to tip1 and methods of use thereof
US20180298094A1 (en) * 2017-04-17 2018-10-18 Ksl Biomedical Llc Monoclonal antibodies targeted to human taxilin alpha and methods for use of same
KR102086649B1 (ko) * 2017-04-18 2020-04-23 주식회사 굳티셀 Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도
JP2020531002A (ja) 2017-08-15 2020-11-05 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学用ｉｇｇ ｆｃ変異体
CN107779500A (zh) * 2017-10-25 2018-03-09 上海药明生物技术有限公司 一种快速获取大鼠杂交瘤细胞单克隆抗体序列的测序方法及引物序列
CA3089653A1 (en) 2018-03-08 2019-09-12 Phanes Therapeutics, Inc. Anti-claudin 18.2 antibodies and uses thereof
US11814434B2 (en) * 2018-03-13 2023-11-14 Tusk Therapeutics Ltd. Anti-CD25 for tumour specific cell depletion
TW202003562A (zh) * 2018-03-14 2020-01-16 中國大陸商北京軒義醫藥科技有限公司 抗密連蛋白18.2(cldn18.2)抗體
EP3878863A4 (en) * 2018-08-27 2022-06-22 Nanjing Sanhome Pharmaceutical Co., Ltd. ANTI-CLAUDIN18.2 ANTIBODIES AND ITS USE
SG11202105885WA (en) * 2018-12-07 2021-07-29 Zlip Holding Ltd Anti-claudin antibodies and uses thereof
MX2021007939A (es) 2018-12-28 2021-10-22 Nanjing Genscript Biotech Co Ltd Porciones de union a claudina 18.2 y usos de estas.
WO2020135201A1 (zh) 2018-12-28 2020-07-02 四川科伦博泰生物医药股份有限公司 一种抗体及其用途
CN114106183B (zh) * 2019-01-15 2023-06-23 浙江道尔生物科技有限公司 抗cld18a2纳米抗体及其应用
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
KR20210134321A (ko) * 2019-02-01 2021-11-09 노바록 바이오테라퓨틱스 리미티드 항-클라우딘 18 항체 및 이의 이용 방법
MY208022A (en) * 2019-04-01 2025-04-08 Shanghai hengrui pharmaceutical co ltd Anti-claudin 18.2 antibody and application thereof
KR20220012262A (ko) * 2019-05-24 2022-02-03 산유 바이오파마슈티컬스 씨오., 엘티디. 신형 cldn18.2 결합분자
CN111978402B (zh) * 2019-05-24 2022-06-28 三优生物医药(上海)有限公司 新型cldn18.2结合分子
JP2022541435A (ja) 2019-07-17 2022-09-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン１８抗体及びがんを処置する方法
KR20220045040A (ko) * 2019-08-20 2022-04-12 쑤저우 트랜스센타 테라퓨틱스 컴퍼니 리미티드 신규 항-cldn18.2 항체
CN112574307B (zh) * 2019-09-29 2023-11-28 迈威(上海)生物科技股份有限公司 抗人Claudin18.2抗体及其应用
EP4054648A4 (en) 2019-11-05 2023-12-27 LaNova Medicines Limited ANTIBODY DRUG CONJUGATES DIRECTED AGAINST CLAUDIN 18.2
CN114901696B (zh) * 2019-12-06 2025-08-05 斯迪安生物技术公司 人源化cldn18.2抗体
BR112022012327A2 (pt) 2019-12-23 2022-10-18 Sotio Biotech A S Anticorpos ou fragmentos dos mesmos, ácido nucleico, vetor e célula hospedeira
KR20220121873A (ko) * 2020-01-03 2022-09-01 크라제 메디컬 씨오 리미티드 항-클라우딘 18.2 항체 및 그 용도
IL296781A (en) 2020-03-30 2022-11-01 BioNTech SE Rna compositions targeting claudin-18.2
CN113493515B (zh) * 2020-04-02 2023-03-28 广东菲鹏制药股份有限公司 抗cldn18a2的抗体以及治疗肿瘤的药物
EP4151235A4 (en) * 2020-05-15 2025-08-06 Sichuan Kelun Biotech Biopharmaceutical Co Ltd ANTIBODY-DRUG CONJUGATE, ITS PREPARATION METHOD AND ITS USE
CN111808194B (zh) * 2020-07-13 2021-04-20 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体
CN114222761B (zh) * 2020-07-14 2024-02-20 浙江道尔生物科技有限公司 一种抗cld18a2的单域抗体
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
WO2022140556A1 (en) * 2020-12-22 2022-06-30 Eutropics Pharmaceuticals, Inc. Methods and compositions related to bcl2 and bim heterodimer antibodies
PE20231561A1 (es) 2020-12-23 2023-10-03 Sotio Biotech A S Conjugados anticuerpo-farmaco especificos para tumores con claudina 18.2
US20250163157A1 (en) 2022-02-27 2025-05-22 Boehringer Ingelheim International Gmbh Bispecific antibodies against cd277 and a tumor-antigen
CN114836388A (zh) * 2022-06-07 2022-08-02 江苏亲科生物研究中心有限公司 Claudin18.2单克隆抗体及其制备方法和用途
IL319682A (en) 2022-10-06 2025-05-01 BioNTech SE RNA complexes targeting claudin-18.2
WO2024074211A1 (en) 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2
CN119462924A (zh) * 2023-08-10 2025-02-18 东莞市朋志生物科技有限公司 一种抗胃泌素17抗体及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
WO1991009974A1 (en) 1989-12-27 1991-07-11 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Diagnostic probe for detecting human stomach cancer
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
WO2002012437A2 (en) 2000-08-03 2002-02-14 Schooten Wim Van Production of humanized antibodies in transgenic animals
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
EP1521775B1 (en) * 2002-06-14 2015-09-09 Immunomedics, Inc. Monoclonal antibody pam4 and its use for diagnosis and therapy of pancreatic cancer
WO2004029207A2 (en) * 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
PL216630B1 (pl) 2002-10-17 2014-04-30 Genmab As Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US20050255041A1 (en) 2004-05-13 2005-11-17 Arius Research, Inc. Cancerous disease modifying antibodies
WO2007053573A2 (en) * 2005-10-31 2007-05-10 Bayer Pharmaceuticals Corporation Treatment of cancer with sorafenib
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer

Also Published As

Publication number Publication date
KR101693365B1 (ko) 2017-01-06
EP2152754B8 (en) 2018-07-04
RU2571923C2 (ru) 2015-12-27
KR20150023951A (ko) 2015-03-05
HRP20230282T3 (hr) 2023-05-12
US20100166779A1 (en) 2010-07-01
CN101687929A (zh) 2010-03-31
HUE061795T2 (hu) 2023-08-28
MX2009012906A (es) 2010-01-25
PT3401334T (pt) 2023-03-27
PL3401334T3 (pl) 2023-05-15
WO2008145338A3 (en) 2009-02-12
CA2687206A1 (en) 2008-12-04
CN103694353A (zh) 2014-04-02
CN101687929B (zh) 2013-11-13
NZ581365A (en) 2012-02-24
US8425902B2 (en) 2013-04-23
EP3401334B1 (en) 2023-02-15
RU2015149617A (ru) 2019-01-14
ZA200907675B (en) 2011-04-28
EP4242236A2 (en) 2023-09-13
JP5995919B2 (ja) 2016-09-21
ES2940775T3 (es) 2023-05-11
KR20100021573A (ko) 2010-02-25
CN103694353B (zh) 2017-12-12
AU2008256489A1 (en) 2008-12-04
RU2682285C2 (ru) 2019-03-18
IL238667A0 (en) 2015-06-30
DK3401334T3 (da) 2023-03-27
KR101751965B1 (ko) 2017-07-11
EP2152754A2 (en) 2010-02-17
SG183773A1 (en) 2012-09-27
KR20170005160A (ko) 2017-01-11
DK3401334T5 (da) 2024-09-23
WO2008145338A2 (en) 2008-12-04
EP1997832A1 (en) 2008-12-03
IL201666A0 (en) 2010-05-31
SI3401334T1 (sl) 2023-05-31
JP6337053B2 (ja) 2018-06-06
IL238668A0 (en) 2015-06-30
EP3401334A1 (en) 2018-11-14
JP2017048170A (ja) 2017-03-09
EP4242236A3 (en) 2023-11-22
JP5816431B2 (ja) 2015-11-18
CA2687206C (en) 2019-07-16
JP2015007053A (ja) 2015-01-15
JP2010528075A (ja) 2010-08-19
LT3401334T (lt) 2023-03-27
BRPI0811907A2 (pt) 2014-11-18
FI3401334T3 (fi) 2023-03-17
KR101585990B1 (ko) 2016-01-19
EP2152754B1 (en) 2018-04-25
RS64065B1 (sr) 2023-04-28
IL201666A (en) 2016-03-31
RU2015149617A3 (es) 2019-02-04
RU2009149205A (ru) 2011-07-10

Similar Documents

Publication Publication Date Title
ES2675375T3 (es) Anticuerpos monoclonales contra claudina 18 para el tratamiento del cáncer
NZ610091A (en) Antibodies
NZ595792A (en) Antibodies specific to cadherin-17
ES2540858T3 (es) Composición farmacéutica para el tratamiento y/o la prevención de cáncer
AR063153A1 (es) Anticuerpo monoclonal para prevenir/tratar el cancer
BR112012021327B8 (pt) anticorpo monoclonal anti-her2 humanizado, método de preparação e uso do mesmo.
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
PH12018500664B1 (en) Anti-lag3 antibodies and uses thereof
EA201592006A1 (ru) Новые биспецифические связывающие молекулы с противоопухолевой активностью
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
PE20150023A1 (es) Proteinas de union a antigeno st2
NZ594682A (en) Fully human antibodies specific to cadm1
EA201500802A1 (ru) Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы
AR095240A1 (es) ANTICUERPOS ANTI-TGF-b MODIFICADOS POR INGENIERÍA GENÉTICA Y FRAGMENTOS DE UNIÓN A ANTÍGENOS
AR073978A1 (es) Anticuerpos humanos de alta afinidad para el receptor il-4-humano
AR106752A1 (es) Proteínas de unión a pd1 / ctla4
MX349513B (es) Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
AR082518A1 (es) Anticuerpos contra il-18r1 y usos de los mismos
NZ587652A (en) Compositions and methods for the treatment of tumor of hematopoietic origin
EA201270769A1 (ru) Антитела к cgrp
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
PE20181076A1 (es) Nuevos moduladores y metodos para su uso
UA110473C2 (uk) Спосіб лікування раку за допомогою пухлиноасоційованого антигену, отриманого із цикліну d1